Who are Adjuvant, non-live RSV vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, HepA-I, hepatitis A vaccine, DTaP, PCV10, measles-rubella vaccine, SARS-CoV-2 Inactivated Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adjuvant-non-live-rsv-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Adjuvant, non-live RSV vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjuvant, non-live RSV vaccine (Adjuvant, non-live RSV vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology / Infectious Disease.

phase 3 Vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Adjuvant, non-live RSV vaccine (Adjuvant, non-live RSV vaccine) — University Health Network, Toronto. An adjuvanted non-live RSV vaccine stimulates the immune system to produce antibodies and cellular immunity against respiratory syncytial virus without containing live virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adjuvant, non-live RSV vaccine TARGET	Adjuvant, non-live RSV vaccine	University Health Network, Toronto	phase 3	Vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
HepA-I	HepA-I	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Hepatitis A virus (HAV)
hepatitis A vaccine, DTaP, PCV10	hepatitis A vaccine, DTaP, PCV10	KEMRI-Wellcome Trust Collaborative Research Program	marketed	combination vaccine
measles-rubella vaccine	measles-rubella vaccine	Sichuan Center for Disease Control and Prevention	marketed	Live attenuated viral vaccine
SARS-CoV-2 Inactivated Vaccine	SARS-CoV-2 Inactivated Vaccine	PT Bio Farma	marketed	Inactivated viral vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

GlaxoSmithKline · 16 drugs in this class
Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
Pfizer · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Henogen · 3 drugs in this class
Pfizer Inc. · 2 drugs in this class
Sanofi · 2 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
BioNTech · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adjuvant, non-live RSV vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/adjuvant-non-live-rsv-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab